普拉替尼治疗RET融合阳性非小细胞肺癌(含一线治疗)的安全性与疗效:ARROW研究更新
ARROW是一项多队列、开放标签、I/II期研究,评估普拉替尼400 mg每日一次治疗RET融合阳性非小细胞肺癌。初治患者客观缓解率72%,既往铂类化疗患者59%;初治患者中位缓解持续时间未达到,既往化疗患者为22.3个月。普拉替尼在初治晚期RET融合阳性非小细胞肺癌中显示稳健疗效且总体耐受良好。
要点
- 初治RET融合阳性NSCLC患者客观缓解率为72%(54/75;95%CI 60%至82%)。
- 既往铂类化疗患者客观缓解率为59%(80/136;95%CI 50%至67%),中位缓解持续时间22.3个月。
- 初治患者中最常见3-4级治疗相关不良事件为中性粒细胞减少(18%)、高血压(10%)。
核心结论
- 普拉替尼在初治晚期RET融合阳性非小细胞肺癌患者中产生稳健疗效且总体耐受良好。
- 确证性III期AcceleRET Lung研究(NCT04222972)比较普拉替尼与一线标准治疗的结果待报告。
研究设计与样本
- ARROW为多队列、开放标签、I/II期研究。
- 纳入年龄≥18岁、局部晚期或转移性实体瘤、ECOG体能状态0-2(后为0-1)的患者。
- 普拉替尼起始剂量为推荐II期剂量400 mg每日一次,直至疾病进展、不耐受、撤回知情同意或研究者决定。
- II期共同主要终点为盲法独立中心评审的客观缓解率和安全性。
- 2017年3月17日至2020年11月6日(数据截止)共入组281例RET融合阳性非小细胞肺癌患者;疗效分析入组截止日期为2020年5月22日。
主要发现
- 初治患者客观缓解率为72%(54/75;95%CI 60%至82%),既往铂类化疗患者为59%(80/136;95%CI 50%至67%)。
- 初治患者中位缓解持续时间未达到,既往铂类化疗患者为22.3个月。
- 所有初治患者和97%的既往铂类化疗患者观察到肿瘤缩小;中位无进展生存期分别为13.0个月和16.5个月。
- 在可测量颅内转移灶患者中,颅内缓解率为70%(7/10;95%CI 35%至93%),所有患者均接受过既往全身治疗。
- 截至数据截止时启动普拉替尼治疗的初治RET融合阳性非小细胞肺癌患者(n=116)中,最常见3-4级治疗相关不良事件为中性粒细胞减少(18%)、高血压(10%)、血肌酸磷酸激酶升高(9%)和淋巴细胞减少(9%);总体7%(20/281)因治疗相关不良事件停药。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: RET fusions are present in 1%-2% of non-small-cell lung cancer (NSCLC). Pralsetinib, a highly potent, oral, central nervous system-penetrant, selective RET inhibitor, previously demonstrated clinical activity in patients with RET fusion-positive NSCLC in the phase I/II ARROW study, including among treatment-naive patients. We report an updated analysis from the ARROW study. PATIENTS AND METHODS: ARROW is a multi-cohort, open-label, phase I/II study. Eligible patients were ≥18 years of age with locally advanced or metastatic solid tumours and an Eastern Cooperative Oncology Group performance status of 0-2 (later 0-1). Patients initiated pralsetinib at the recommended phase II dose of 400 mg once daily until disease progression, intolerance, consent withdrawal, or investigator's decision. The co-primary endpoints (phase II) were overall response rate (ORR) by blinded independent central review and safety. RESULTS: Between 17 March 2017 and 6 November 2020 (data cut-off), 281 patients with RET fusion-positive NSCLC were enrolled. The ORR was 72% [54/75; 95% confidence interval (CI) 60% to 82%] for treatment-naive patients and 59% (80/136; 95% CI 50% to 67%) for patients with prior platinum-based chemotherapy (enrolment cut-off for efficacy analysis: 22 May 2020); median duration of response was not reached for treatment-naive patients and 22.3 months for prior platinum-based chemotherapy patients. Tumour shrinkage was observed in all treatment-naive patients and in 97% of patients with prior platinum-based chemotherapy; median progression-free survival was 13.0 and 16.5 months, respectively. In patients with measurable intracranial metastases, the intracranial response rate was 70% (7/10; 95% CI 35% to 93%); all had received prior systemic treatment. In treatment-naive patients with RET fusion-positive NSCLC who initiated pralsetinib by the data cut-off (n = 116), the most common grade 3-4 treatment-related adverse events (TRAEs) were neutropenia (18%), hypertension (10%), increased blood creatine phosphokinase (9%), and lymphopenia (9%). Overall, 7% (20/281) discontinued due to TRAEs. CONCLUSIONS: Pralsetinib treatment produced robust efficacy and was generally well tolerated in treatment-naive patients with advanced RET fusion-positive NSCLC. Results from the confirmatory phase III AcceleRET Lung study (NCT04222972) of pralsetinib versus standard of care in the first-line setting are pending.
引用
- Griesinger F, Curigliano G, Thomas M, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022. PMID: 35973665. doi:10.1016/j.annonc.2022.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。